Thymosin alpha 1 for use in treatment of cystic fibrosis
View Patent ↗The present invention concerns Thymosin alpha 1 (Tα1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
1. A method of treating inflammation attributed to infection associated with cystic fibrosis in a patient, comprising administering to the patient in need thereof a pharmaceutical composition comprising Thymosin alpha 1 .
2. The method of claim 1 , further comprising administering to the patient at least one agent selected from the group consisting of antibiotic, antifungal, cystic fibrosis transmembrane conductance regulator (CFTR) corrector, CFTR potentiator, and anti- inflammatory agent.
3. The method of claim 2 , wherein the antibiotic agent is selected from the group consisting of tobramycin, ciprofloxacin, and colistin.
4. The method of claim 2 , wherein the antifungal agent is selected from the group consisting of itraconazole and amphotericin B.
5. The method of claim 2 , wherein the CFTR corrector or potentiator agent is selected from the group consisting of ivacaftor and lumacaftor.
6. The method of claim 2 , wherein the anti-inflammatory agent is ibuprofen.
7. The method of claim 2 , wherein Thymosin alpha 1 and the at least one agent are administered to the patient together, separately, or sequentially.
8. The method of claim 1 , wherein the pharmaceutical composition comprises one or more excipients and/or coadjuvants.
9. The method of claim 1 , wherein the inflammation is chronic inflammation.
10. The method of claim 1 , wherein the patient has a CFTR mutation ΔF508.